Quidel Reports

You may have missed

FDA receives letter of interest (LOI) to test specificity of molecular membrane antibodies as part of ISTAND drug development tool pilot program

3 weeks ago Arlette

ASX Health shares: PromarkerD canagliflozin compared to blood protein canagliflozin is effective

3 weeks ago Arlette

Acrivon Therapeutics announced that the FDA has granted a Fast Track designation for ACR-368 in the platinum-resistant endometrial and ovarian cancer biospace.

3 weeks ago Arlette

FDA approves first RSV vaccine developed by GlaxoSmithKline

1 month ago Arlette

Are women with cancer less active on dating sites

2 months ago Arlette